Back to Search
Start Over
Varenicline: For smoking cessation
- Source :
- Kathmandu University Medical Journal. 7:162-164
- Publication Year :
- 1970
- Publisher :
- Nepal Journals Online (JOL), 1970.
-
Abstract
- Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal. As a nAChR partial agonist, Varenicline attenuates the craving and withdrawal symptoms that occur with abstinence from nicotine and also reduces the rewarding effects of nicotine obtained from smoking in patients who lapse. Clinical trials have demonstrated superior efficacy of this drug over Bupropion-SR for achieving abstinence from smoking, and Varenicline has also been shown to significantly delay smoking relapse. As the latest agent approved for smoking cessation, the mechanism of action, efficacy, and safety of Varenicline has been reviewed in this paper. Key words: α4β2 nicotinic acetylcholine receptor; Varenicline; smoking cessation; partial agonist. DOI: 10.3126/kumj.v7i2.2714 Kathmandu University Medical Journal (2009) Vol.7, No.2 Issue 26, 162-164
- Subjects :
- medicine.medical_specialty
medicine.medical_treatment
media_common.quotation_subject
Craving
Partial agonist
Nicotine
chemistry.chemical_compound
Quinoxalines
Internal medicine
medicine
Humans
Nicotinic Agonists
Varenicline
media_common
Bupropion
business.industry
Tobacco Use Disorder
General Medicine
Benzazepines
Abstinence
Nicotine replacement therapy
chemistry
Anesthesia
Smoking cessation
Smoking Cessation
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 18122078 and 18122027
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Kathmandu University Medical Journal
- Accession number :
- edsair.doi.dedup.....5c996ea48767d5163d04f9f98ef64c01